Long‐Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1‐Associated Plexiform Neurofibromas
Pediatric Blood & Cancer · 2026-09 · 73 (9)
DOI: 10.1002/1545-5017.70477 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 29.07.2026. Verfasst von Alan H Siegel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Children's National Hospital, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Benzimidazoles, Neurofibroma, Plexiform, Neurofibromatosis 1, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: National Institutes of Health (NIH).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Selumetinib, a mitogen‐activated protein kinase kinase inhibitor, was the first Food and Drug Administration‐approved treatment for children with neurofibromatosis type 1‐associated inoperable plexiform neurofibromas. We evaluated hematologic effects in 98 pediatric participants from the SPRINT Phase 1/2 trial (NCT01362803) with a median follow‐up of 5.1 years (range: 0.2–11 years). Over 90% of values for white blood cell count, platelet count, absolute neutrophil count, and absolute lymphocyte count remained within normal limits across timepoints. There was a statistically significant, but unlikely clinically significant, decrease in absolute lymphocyte count and an increase in mean corpuscular volume. Selumetinib was not associated with apparent clinically significant hematologic changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's National Hospital, Washington, District of Columbia, USA.
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
- Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA.
- Lurie Children's Hospital, Chicago, Illinois, USA.
- Riley Children's Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, USA.
ORCID-Profile: Alan H Siegel, Miriam Bornhorst, Brian D Weiss
Förderung
- National Institutes of Health (NIH)
Zitieren
APA
Siegel, A. H., Baldwin, A., Heisey, K., Herrera, K., Dufek, A., Patel, H., Kim, A., Bornhorst, M., Weiss, B. D., Blank, P., Fisher, M. J., Widemann, B. C., & Gross, A. M. (2026). Long‐Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1‐Associated Plexiform Neurofibromas. Pediatric Blood & Cancer, 73(9). https://doi.org/10.1002/1545-5017.70477
Vancouver
Siegel AH, Baldwin A, Heisey K, Herrera K, Dufek A, Patel H, et al. Long‐Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1‐Associated Plexiform Neurofibromas. Pediatric Blood & Cancer. 2026;73(9). doi:10.1002/1545-5017.70477
BibTeX
@article{Siegel2026,
author = {Siegel, Alan H and Baldwin, Andrea and Heisey, Kara and Herrera, Kailey and Dufek, Anne and Patel, Hemaxi and Kim, AeRang and Bornhorst, Miriam and Weiss, Brian D and Blank, Peter de and Fisher, Michael J and Widemann, Brigitte C and Gross, Andrea M},
title = {Long‐Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1‐Associated Plexiform Neurofibromas},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {9},
doi = {10.1002/1545-5017.70477}
}
EUVIMED